Cargando…
Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
The inflammatory response in the CF airway begins early in the disease process and becomes persistent through life in most patients. Inflammation, which is predominantly neutrophilic, worsens airway obstruction and plays a critical role in the development of structural lung damage. While cystic fibr...
Autores principales: | Perrem, Lucy, Ratjen, Felix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516261/ https://www.ncbi.nlm.nih.gov/pubmed/33013419 http://dx.doi.org/10.3389/fphar.2020.576293 |
Ejemplares similares
-
Letting It All Out: Neutrophils in Early Cystic Fibrosis Airway Inflammation
por: Perrem, Lucy, et al.
Publicado: (2019) -
Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023) -
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
por: Mitri, Christie, et al.
Publicado: (2020) -
Editorial: Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
por: Ribeiro, Carla Maria Pedrosa, et al.
Publicado: (2021) -
Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease
por: Voynow, Judith A., et al.
Publicado: (2020)